This is cancer that starts in the bladder, the organ that stores urine. It's also called bladder cancer or bladder tumors. It's the most common type of bladder cancer.
Every report comes from a Lived member, sent anonymously.
Have you had Transurethral Resection of Bladder for Bladder Cancer?
Bladder cancer begins when cells in the lining of the bladder, the hollow organ that stores urine, start growing out of control. Almost all bladder cancers are urothelial carcinomas (also called transitional cell carcinomas), which start in the stretchy cells that line the bladder and the rest of the urinary tract. Squamous cell carcinoma, adenocarcinoma and small cell carcinoma are rare types. The most important distinction is how deeply the cancer has grown. Most bladder cancers are non-muscle-invasive: they are confined to the lining or the tissue just beneath it and have not reached the muscle wall. These can often be cured, though they frequently come back. Muscle-invasive cancer has grown into the muscle wall or beyond, is more likely to spread and needs more extensive treatment. The most common sign is blood in the urine, which can look rusty, pink or bright red, or may be found only on a urine test. It is often painless and may disappear for weeks before returning. Some people instead notice frequent or urgent urination, burning when they urinate or waking at night to urinate. Infections, kidney or bladder stones and an enlarged prostate cause these symptoms far more often, which is why they need checking rather than assuming the worst.
Bladder cancer develops when the DNA in cells lining the bladder is damaged in ways that change how they grow and divide. Tobacco smoking is the major preventable risk factor. Cancer-causing chemicals in smoke are absorbed into the blood, filtered by the kidneys and concentrated in urine, so the bladder lining is bathed in them for hours at a time. Risk also rises with age and is higher in men and in White people in the United States. Other contributors include long-term workplace exposure to certain dyes, paints, metals and petroleum products; a family history of bladder cancer; earlier radiation to the pelvis or treatment with the chemotherapy drugs cyclophosphamide or ifosfamide; drinking well water with high arsenic levels; long-term use of urinary catheters; and chronic infection with Schistosoma haematobium, a parasite common in parts of Africa and the Middle East but rare in the United States. These are risk factors, not certain causes. Many people with them never develop bladder cancer, and some people with none of them do.
Evaluation usually starts with a medical history, a physical exam and a urine sample checked for blood, abnormal cells and infection. Because infection and stones are common explanations, those are ruled out along the way. The key test is cystoscopy: a urologist passes a thin tube with a light and camera through the urethra to look at the bladder lining directly. If something abnormal is seen, tissue is removed for a pathologist to examine under a microscope. Often the whole visible tumor is removed in a procedure called transurethral resection of bladder tumor (TURBT), done under anesthesia through the same route, which both confirms the diagnosis and is the first treatment. A CT urogram, a CT scan taken after contrast dye is injected into a vein, checks the kidneys and the tubes that drain them, since the same type of cancer can occur there. The pathology report describes two things that shape every later decision. Stage is how far the cancer has grown: stage 0 is confined to the lining, stage I has reached the tissue beneath it, stage II has reached the muscle, stage III has spread into surrounding fat, nearby organs or pelvic lymph nodes, and stage IV has spread farther. Grade describes how abnormal the cells look; high-grade cancers tend to grow and spread faster than low-grade ones. If the first resection did not include muscle tissue or leaves doubt, a second resection may be done. For cancers that may be invasive, CT or MRI scans of the abdomen and pelvis and imaging of the chest check for spread.
Treatment depends mainly on whether the cancer has reached the muscle wall, along with its grade, the number and size of tumors, and a person's overall health and preferences. For non-muscle-invasive cancer, TURBT removes the visible tumor. Because these cancers often return, medicine is usually placed directly into the bladder through a catheter, called intravesical therapy, to destroy remaining cancer cells. A single dose of chemotherapy such as mitomycin or gemcitabine may be given around the time of surgery for lower-risk tumors. For higher-risk tumors, including high-grade cancers and carcinoma in situ (a flat, high-grade cancer of the lining), the usual choice is BCG (bacillus Calmette-Guérin), a weakened bacterium related to the one that causes tuberculosis, which provokes an immune response that attacks cancer cells. BCG is typically given weekly for six weeks and then as maintenance treatments for up to one to three years. Flu-like symptoms, burning and frequent urination for a few days after each treatment are common. When high-risk cancer keeps returning despite BCG, options include removing the bladder, the immunotherapy pembrolizumab (Keytruda) given by vein, or newer medicines placed in the bladder. For muscle-invasive cancer, the standard approach is radical cystectomy, removal of the whole bladder and nearby lymph nodes. In men this usually includes the prostate and seminal vesicles; in women it may include the uterus, ovaries and part of the vagina. Chemotherapy that includes cisplatin given before surgery helps people live longer than surgery alone for those well enough to receive it. Enfortumab vedotin (Padcev), a drug that carries a chemotherapy agent to cells with a specific surface protein, is approved together with pembrolizumab before and after cystectomy for adults with muscle-invasive cancer. For some people at high risk of recurrence after surgery, the immunotherapy nivolumab (Opdivo) may follow. People who cannot have, or choose not to have, cystectomy may receive radiation combined with chemotherapy, which can keep the bladder in place but requires ongoing cystoscopy checks. Removing the bladder means creating a new way to pass urine, called a urinary diversion. An ileal conduit uses a short piece of intestine to carry urine to an opening (stoma) on the abdomen, where it drains continuously into a bag. A continent pouch stores urine inside the body and is emptied with a catheter through a small stoma. A neobladder is built from intestine and attached to the urethra so urine leaves the usual way. Cystectomy commonly affects sex: men no longer produce semen and many have erection problems, and women may find intercourse less comfortable after part of the vagina is removed. These effects are worth discussing before surgery, since nerve-sparing techniques and reconstruction are sometimes possible. For cancer that has spread, treatment aims to slow the cancer, relieve symptoms and extend life. Enfortumab vedotin with pembrolizumab, cisplatin-based chemotherapy with or without immunotherapy, and other immunotherapies are common first choices. Testing the tumor for genetic changes can open further options, such as erdafitinib (Balversa) for cancers with certain FGFR gene changes. Clinical trials are an option at many stages.
Non-muscle-invasive bladder cancer is often curable, but it tends to come back, sometimes years later and often in a different part of the bladder. For that reason, follow-up is a long-term commitment. Most people have cystoscopy and urine tests every three to six months at first, with visits becoming less frequent if the bladder stays clear. A recurrence found early can usually be removed with another TURBT. Repeated resections over many years can scar the bladder and reduce how much urine it holds, leading to more frequent urination. After cystectomy, recovery takes several weeks, and the bigger adjustment is learning to live with the new urinary system. Ostomy nurses teach stoma and bag care, and most people return to work, travel, exercise and intimacy. People with a neobladder urinate on a schedule because they no longer feel the usual urge, and nighttime leaking is common, especially early on. Follow-up imaging and blood tests continue after surgery to watch for recurrence and check kidney function. Outlook depends heavily on stage. In US data, people with carcinoma in situ alone are 97 percent as likely as the general population to be alive five years after diagnosis; that figure is 71 percent for cancer still confined to the bladder, 39 percent once it has reached nearby lymph nodes or organs, and 8 percent when it has spread to distant organs. These are averages from people treated years ago and cannot predict any one person's course, and newer treatments are not yet reflected in them. People who keep smoking are more likely to have their cancer return than people who do not smoke. Whether quitting after diagnosis lowers that risk is still being studied, but stopping has many other health benefits and support is available.
See a clinician about any blood in the urine, even if it happened only once, caused no pain or has since cleared, and about frequent, urgent or painful urination that does not settle or keeps returning. If you have been treated for bladder cancer, report new blood in the urine to your urology team rather than waiting for the next scheduled check. During BCG treatment, call your care team right away for a high fever that does not go away, which can signal a rare but serious BCG infection. Get emergency care if you cannot pass urine at all or have severe pain in the lower abdomen, for example when blood clots block the flow.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Bladder Cancer is like, what's helped you, or ask the community a question.